Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75

Published 06/06/2025, 11:16
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75

On Friday, Ascendiant Capital analysts raised the 12-month price target for Lucid (NASDAQ:LCID) Diagnostics Inc (NASDAQ: LUCD) to $7.75 from the previous target of $7.50. The analysts maintained their Buy rating on the stock, citing an attractive valuation. The new target represents significant upside potential from the current price of $1.21, though InvestingPro data shows the stock has already gained over 44% in the past six months.

The analysts highlighted the potential for significant upside from the current share price, which they believe justifies the price target increase. Their assessment was based on a net present value analysis that considers the company’s high risks alongside substantial upside opportunities. According to InvestingPro analysis, LUCD faces challenges with weak gross profit margins and rapid cash burn, though it maintains moderate debt levels.

Lucid Diagnostics is currently trading on the NASDAQ exchange under the ticker LUCD. The analysts’ decision to maintain the Buy rating reflects confidence in the company’s future prospects despite its inherent risks.

The revised price target suggests optimism about Lucid Diagnostics’ potential growth, with the analysts emphasizing the balance between risks and opportunities.

In other recent news, Lucid Diagnostics Inc. reported its first-quarter 2025 earnings with revenue totaling $800,000, a figure that fell short of both Cantor Fitzgerald’s projection of $1.7 million and the FactSet consensus of $1.2 million. Despite this, the company performed 3,034 EsoGuard tests, which exceeded expectations. Cantor Fitzgerald maintained its Overweight rating on Lucid Diagnostics, with a price target of $2.00, indicating confidence in the company’s prospects. Lucid Diagnostics is on the verge of potentially securing Medicare Coverage for its EsoGuard product, which is anticipated to be a significant catalyst for future revenue growth.

Additionally, Lucid Diagnostics announced its inclusion in the Russell 2000 and Russell 3000 Indexes, a development expected to enhance its visibility among institutional investors. The company also secured its first positive policy coverage from Highmark Blue Cross Blue Shield, marking a step forward in its reimbursement strategy. Furthermore, Lucid Diagnostics is actively expanding its market presence through strategic partnerships and innovative campaigns, aiming for substantial revenue growth in the coming quarters. The company is also preparing for a large-scale real-world evidence study involving 12,000 patients, which could further bolster its market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.